Inclusion Criteria:

          -  Signed and dated written informed consent.

          -  Subjects ≥ 18 years of age

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

          -  Current diagnosis of any stage I to III malignant solid tumor at high risk of
             metastatic recurrence (deemed by treating physician as patients with ≥ 50% chance of
             cancer metastatic recurrence within 5 years of diagnosis)

          -  Patients must have completed all standard locoregional and systemic therapy for their
             cancer within 120 days of study enrollment.

          -  Administration of an investigational agent prior to enrollment needs to be completed
             at least 30 days prior to enrollment

          -  Patients must have recovered (≤ grade 1 toxicities or grade 2 toxicities well managed
             with optimal medical care) from effects of local (surgery, radiation) or systemic
             treatments.

          -  Platelet count ≥ 100,000 per mL of blood

          -  Hemoglobin ≥ 9/g/dL (may have been transfused)

          -  Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50 mL/min as
             calculated using the Cockcroft-Gault (CG) equation

          -  Total serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 ×
             ULN

          -  INR below upper limit of normal (ULN)

          -  Female patients of childbearing potential and non-sterile males must agree to use at
             least two methods of acceptable contraception from 15 days prior to first trial
             treatment administration until at least 5 months after study participant's final dose
             of study drug

        Note: Females of childbearing potential are defined as those who are not surgically sterile
        or post-menopausal (i.e. patient has not had a bilateral tubal ligation, a bilateral
        oophorectomy, or a complete hysterectomy; or has not been amenorrheic for 12 months without
        an alternative medical cause). Post-menopausal status in females under 55 years of age
        should be confirmed with a serum follicle-stimulating hormone (FSH) level within laboratory
        reference range for postmenopausal women. Non-sterile males are those who have not had a
        vasectomy with documentation of the absence of sperm in the ejaculate.

          -  Patients unable to read/write in English are eligible to participate in the overall
             study but will not participate in the Patient-Reported Outcome questionnaires
             throughout the trial.

          -  Re-enrollment of a subject that has discontinued the study as a pre-treatment screen
             failure (i.e. a consented patient who did not receive study drugs) is permitted. If
             reenrolled, the subject must be re-consented. Only the screening procedures performed
             outside of protocol-specified timing must be repeated.

        Exclusion Criteria:

          -  Evidence of biopsy-proven distant metastatic disease after completion of standard
             treatment

          -  Current use of anti-platelet drugs (ASA, NSAIDs, clopidogrel, argatroban, etc.) or
             anticoagulants (warfarin, heparin products, etc.)

          -  Active malignancy within 5 years prior to current diagnosis except for in situ disease
             or cancer with very high curability rate (i.e. testicular cancer, etc.)

          -  Uncontrolled co-morbid serious systemic illnesses that in the opinion of the
             investigator could compromise therapeutic safety.

          -  No concurrent anticancer therapy. Required washout from prior therapy:

               -  Chemotherapy: 21 days

               -  Major surgery: 14 days (provided wound healing is adequate)

               -  Radiation: 7 days

               -  Investigational/Biologic Therapy: 30 days

          -  Current symptomatic congestive heart failure (New York Heart Association > class II),
             unstable cardiac arrhythmia requiring therapy (e.g. medication or pacemaker), unstable
             angina (e.g. new, worsening or persistent chest discomfort), or uncontrolled
             hypertension (systolic > 160 mmHg or diastolic > 100mmHg). Or any of the following
             occurring within 6 months (180 days) prior to first dose of study drugs: Myocardial
             infarction, coronary/peripheral artery bypass graft, cerebrovascular accident or
             transient ischemic attack. (Use of antihypertensive medication to control blood
             pressure is allowed.)

          -  Ongoing peptic ulcer disease requiring treatment

          -  History of gastrointestinal bleed

          -  Severe gastro-esophageal reflux disease requiring treatment

          -  History of bleeding diathesis

          -  Planned elective major surgical intervention while taking ifetroban

          -  Pregnant or breastfeeding females.

          -  Prisoners or subjects who are involuntarily incarcerated.

          -  Known psychiatric condition, social circumstance, or other medical condition
             reasonably judged by the patient's study physician to unacceptably increase the risk
             of study participation; or to prohibit the understanding or rendering of informed
             consent or anticipated compliance with scheduled visits, treatment schedule,
             laboratory tests and other study requirements.